Hepatitis

The first participant has been enrolled in a Phase 3 clinical trial testing Bluejay Therapeutics’ investigational therapy brelovitug against bulevirtide in adults with chronic…

A gene-editing therapy designed to specifically inactivate a hidden genetic blueprint of the hepatitis B virus (HBV) — the cause of hepatitis B —…

A one-hour point-of-care test for hepatitis C has been cleared for use in Canada, which could help accelerate diagnosis and monitor how people with…

Current approaches to hepatitis B care across the globe are failing to adequately connect patients with treatment, and also to retain them for long-term…

The first participant has been dosed in a Phase 2 clinical trial testing Aligos Therapeutics’ oral treatment candidate ALG-000184 in people chronically infected with…

The proportion of cases of hepatocellular carcinoma (HCC) attributable to fatty liver disease is set to rise in the next 25 years, with obesity…

The first participant has been enrolled in ECLIPSE 3, a Phase 2b clinical trial testing Vir Biotechnology’s combination treatment of tobevibart and elebsiran against…

About 74,000 babies are born each year with the virus that causes hepatitis C, and more than 23,000 of them may still have the…

World Hepatitis Day arrives Monday and advocates are gearing up to break down barriers that stand in the way of a world free from…

Access to hepatitis C treatment and care remains low among children and recently pregnant women in the U.S., according to data from two recently…